Novaliq GmbH

General information
Novaliq GmbH
Im Neuenheimer Feld 515
69120 Heidelberg, Baden-Württemberg
Germany

Contact person: Christian Roesky, Managing Director / Chief Executive Officer
Company main phone: +49 (6221) 502590
Company main fax:  +49 (6221) 5025921
Website:  https://www.novaliq.com
Year founded:2007
Source of foundation:Independent foundation
Corporate description / mission:
Novaliq GmbH is a pharmaceutical company focused on the development and commercialization of ocular therapeutics based on EyeSol® which is designed to unfold the full potential of eye care treatments. NOV03 and CyclASol® are the two late-stage development compounds of the company. Novaliq offers an industry-leading portfolio addressing today's unmet medical needs of millions of patients with eye diseases.
State of ownership: Private / independent
Headquarters: HQ: Yes
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Drug delivery
Primary therapeutic areas:
  • Diseases of the eye / ophthalmology
Business model:
  • Manufacturer
  • Out-licensing
  • R&D
  • Supplier / Distributor
Customer segments:
  • Other
  • Large biotech & big pharma
  • Small biotech
Distribution:
  • Direct (own sales force)
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:7
Phase II:1
Phase III:3
On the market:4
Description of products:
CyclASol®
NOV03
NovaTears®+Omega-3
Technology used:
EyeSol® technology
Collaborations & Clients
Partnering strategy / collaborations:
AFT Pharmaceuticals Ltd
Ursapharm, etc.
X